Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway

Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side effects, and drug resistance, which poses critical challenges in the clinical setting. Acquired resistance of ELTN r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Pharmacol
Hauptverfasser: Chen, Donglai, Zhang, Fuquan, Wang, Jinhui, He, Hua, Duan, Shanzhou, Zhu, Rongying, Chen, Chang, Yin, Lichen, Chen, Yongbing
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2018
Schlagworte:
Pharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6242943/
https://ncbi.nlm.nih.gov/pubmed/30483119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01214
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge